Systemic and Topical Retinoids in the Management of Skin Cancer in Organ Transplant Recipients

Dermatologic Surgery

Volumn 30, Issue 4 II, 2004, Pages 656-661

  De Graaf, Y G L ^a   Euvrard, S ^b   Bouwes Bavinck, J N ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHOLESTEROL; DERMATOLOGICAL AGENT; ETRETIN; ETRETINATE; ISOTRETINOIN; PLACEBO; RETINOIC ACID; RETINOID; TRIACYLGLYCEROL;

ACTINIC KERATOSIS; ARTHRALGIA; ARTICLE; CANCER INHIBITION; CHEILITIS; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; GASTRITIS; HAIR LOSS; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY DISEASE; LIVER TOXICITY; LOW DRUG DOSE; MUSCULOSKELETAL DISEASE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PRURITUS; RECIPIENT; SIDE EFFECT; SKIN CARCINOMA; SKIN IRRITATION; SKIN MANIFESTATION; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 1942443910     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2004.30152.x     Document Type: Article

References (39)

1. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk of neoplasia in renal transplant patients. Lancet 1995;346:403-6.
2. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91.
3. Hartevelt MM, Bouwes Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990;49:506-9.
4. Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia: a follow-up study. Transplantation 1996;61:715-21.
5. DiGiovanna JJ. Posttransplantation skin cancer: scope of the problem, management, and role for systemic retinoid chemoprevention. Transplant Proc 1998;30:2771-5.
6. van Zuuren EJ, Posma AN, Scholtens RE, et al. Resurfacing the back of the hand as treatment and prevention of multiple skin cancers in kidney transplant recipients. J Am Acad Dermatol 1994;31(5 Pt 1):760-4.
7. DiGiovanna JJ. Retinoid chemoprevention in patients at high risk for skin cancer. Med Pediatr Oncol 2001;36:564-7.
8. Euvrard S, Kanitakis J, Thivolet J, Claudy A. Retinoids for the management of dermatological complications of organ transplantation. Biodrugs 1997;8:176-84.
9. DiGiovanna JJ. Retinoids for the future: oncology. J Am Acad Dermatol 1992;27(6 Pt 2):S34-7.
10. Niles RM. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition 2000;16:1084-9.
11. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181-93.
12. Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC. Current use and future potential role of retinoids in dermatology. Drugs 1997;53:358-88.
13. Bartsch D, Boye B, Baust C, zur HH, Schwarz E. Retinoic acid-mediated repression of human papillomavirus 18 transcription and different ligand regulation of the retinoic acid receptor beta gene in non-tumorigenic and tumorigenic HeLa hybrid cells. EMBO J 1992;11:2283-91.
14. Khan MA, Jenkins GR, Tolleson WH, Creek KE, Pirisi L. Retinoic acid inhibition of human papillomavirus type 16-mediated transformation of human keratinocytes. Cancer Res 1993;53:905-9.
15. Rook AH, Jaworsky C, Nguyen T, et al. Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Transplantation 1995;59:714-9.
16. Gibson GE, O'Grady A, Kay EW, Leader M, Murphy GM. Langerhans cells in benign, premalignant and malignant skin lesions of renal transplant recipients and the effect of retinoid therapy. J Eur Acad Dermatol Venereol 1998;10:130-6.
17. Blokx WA, Smit JV, de Jong EM, et al. Retinoids strongly and selectively correlate with keratin 13 and not keratin 19 expression in cutaneous warts of renal transplant recipients. Arch Dermatol 2002;138:61-5.
18. De Lacharriere O, Escoffier C, Gracia AM, et al. Reversal effects of topical retinoic acid on the skin of kidney transplant recipients under systemic corticotherapy. J Invest Dermatol 1990;95:516-22.
19. Sankaranarayanan R, Mathew B. Retinoids as cancer-preventive agents. IARC Sci Publ 1996;139:47-59.
20. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988;318:1633-7.
21. Moon TE, Levine N, Cartmel B, Bangert JL. Retinoids in prevention of skin cancer. Cancer Lett 1997;114:203-5.
22. Tangrea JA, Edwards BK, Taylor PR, et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst 1992;84(5):328-32.
23. Staels B. Regulation of lipid and lipoprotein metabolism by retinoids. J Am Acad Dermatol 2001;45:158-67.
24. Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol 2001;45:515-9.
25. Shuttleworth D, Marks R, Griffin PJ, Salaman JR. Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. Q J Med 1988;68:717-25.
26. Kelly JW, Sabto J, Gurr FW, Bruce F. Retinoids to prevent skin cancer in organ transplant recipients. Lancet 1991;338:1407.
27. Gibson GE, O'Grady A, Kay EW, Murphy GM. Low-dose retinoid therapy for chemoprophylaxis of skin cancer in renal transplant recipients. J Eur Acad Dermatol Venereol 1998;10:42-7.
28. Bouwes Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995;13:1933-8.
29. de Sevaux RG, Smit JV, de Jong EM, van de Kerkhof PC, Hoitsma AJ. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol 2003;49:407-12.
30. Yuan ZF, Davis A, Macdonald K, Bailey RR. Use of acitretin for the skin complications in renal transplant recipients. N Z Med J 1995;108:255-6.
31. McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999;140:656-60.
32. McNamara IR, Muir J, Galbraith AJ. Acitretin for prophylaxis of cutaneous malignancies after cardiac transplantation. J Heart Lung Transplant 2002;21:1201-5.
33. George R, Weightman W, Russ GR, Bannister KM, Mathew TH. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002;43:269-73.
34. Bellman BA, Eaglstein WH, Miller J. Low dose isotretinoin in the prophylaxis of skin cancer in renal transplant patients. Transplantation 1996;61:173.
35. Andany MA, Kasiske BL. Dyslipidemia and its management after renal transplantation. J Nephrol 2001;14(Suppl 4):S81-8.
36. Euvrard S, Verschoore M, Touraine JL, et al. Topical retinoids for warts and keratoses in transplant recipients. Lancet 1992;340:48-9.
37. Euvrard S, Kanitakis J, Claudy A. Topical retinoids for the management of dysplastic epithelial lesions. In: Skin Diseases after Organ Transplantation. Montrouge: John Libbey Eurotext; 1998. p. 175-82.
38. Smit JV, Cox S, Blokx WA, et al. Actinic keratoses in renal transplant recipients do not improve with calcipotriol cream and all-trans retinoic acid cream as monotherapies or in combination during a 6-week treatment period. Br J Dermatol 2002;147:816-8.
39. Vandeghinste N, De Bersaques J, Geerts ML, Kint A. Acitretin as cancer chemoprophylaxis in a renal transplant recipient. Dermatology 1992;185:307-8.